Precompetitive Collaboration in Oncology: Imaging Science

Institute of Medicine

February 10, 2010

Gary J. Kelloff, MD
National Cancer Institute
OBQI: Unique HHS Partnership

The Oncology Biomarkers Qualification Initiative (OBQI) is a new and innovative collaboration among NCI, FDA, and CMS designed to qualify biomarkers for use in clinical trials – and ultimately speed better agents to cancer patients.*

*Tri-partite MOU signed 01/23/2006
OBQI Coordinates Cross-HHS Goals for Biomarker Validation and Clinical Use

OBQI

Develop biomarker technologies and validation protocols to improve detection, diagnosis, treatment, and prevention of cancer

Develop guidance for the use of biomarkers to facilitate cancer drug development

Make informed decisions about reimbursement of new or existing treatment regimens based on biomarker-guided knowledge
Value Proposition/Benefit for Partners in Public Private Partnership (PPP)

- **Patients:** Better Clinical Data, More Effective Treatment/Management
- **FDA:** Provides for Evidence-Based Regulatory Policy
- **Pharma:** More Efficient Drug Development and Approval Path, Better Early Response Criteria
- **Device Industry:** Larger Market for PET/CT and PET/MRI Scanners
- **CMS:** Helps Define Reasonableness and Need
- **Academia/NCI:** Better Clinical Data, More Effective Treatment/Management
FNIH Biomarkers Consortium Cancer Steering Committee
Validation/Qualification of Imaging-Based Biomarkers

Improved Imaging-Based Biomarkers:

• FDG-PET as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in NSCLC

• Evaluation of FDG-PET Imaging as a Prognostic Marker in Non-Hodgkin’s Lymphoma

• Qualification of DCE-MRI To Predict and Monitor Patient Response to Cancer Therapy

Multiplex Projects with New Biomarkers and New Trial Designs in Combination with Measurable Endpoints (e.g., MR Volume):

• I-SPY TRIAL-2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Human Carcinogenesis is a Multi-Year Process

Dysplasia=Intraepithelial Neoplasia (IEN)

Normal

Initiated

Mild

Moderate

Severe

CIS

Cancer

Colon

Head & Neck

Esophagus

Cervix

Lung (Smokers)

Skin (Non-Melanoma)

Breast

Prostate

Bladder

5–20 yrs

ADENOMA

TOBACCO USE

4–10 yrs

BARRETT'S

est. 9–13 yrs

20–40 pack-yrs

30–40 yrs

ATYPICAL HYPERPLASIA

14–18 yrs

20 yrs

Normal

Initiated

Mild

Moderate

Severe

CIS

Cancer

Human Carcinogenesis is a Multi-Year Process

### Molecular Biomarkers of Carcinogenesis

Dysplasia = Intraepithelial Neoplasia (IEN)

<table>
<thead>
<tr>
<th>Normal</th>
<th>Initiated</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>CIS</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Prostate
- AR, SRD5A2, CYP17, GSTP1
- Genetic Susceptibility to Infection
- ↑AR, ↓GSTP1, ↑TERT, ↑NKX3.1, ↑8p, 13q, ↓10q, ↓16q, ↑7p, ↑7q, ↑DNA Ploidy, ↑IGF, ↑EGFR, ↑HER-2, ↑PCNA, ↑Ki67
- ↓p53, ↑VEGF, ↑FGF, ↑Cadherins, ↑MMPs, ↑PSA

#### Colon
- ↓APC, ↑BCL-2, c-MYC
- Hypomethylation
- ↑RAS, ↑COX-2
- ↑SMAD 2, ↑SMAD 4, ↑DCC, ↑STAT3
- ↑p53, ↑p16, 7q, ↑VEGF, ↑Cyclin D1
- p15, Bub1, 22q, CD44
- 8p, ↑PA, ↑MMP, ↑CEA, ↑E-Cadherin

#### Breast
- E₂ Metabolism, Cyt P450, ↑ER, ↑PR, ↓DNA Repair
- ↑DNA Adducts, Genomic Instability, ↓Thrombospodin
- ↑p53, ↑Cyclin D1, ↑BRCA1, 2, ↑IGF, ↑Aneuploidy
- ↑ERB-B2, ↑EGFR, ↑VEGF, ↑RXR, ↑NM23
- ↑Angiogenesis, ↑Collagenase, ↑FGF

#### Lung
- ↓3p, ↓9p, ↓13q, ↓5p, ↓P16
- ↑53, ↑K-RAS, c-myc, 22q, ↓18q, ↑β-Catenin

#### Head & Neck
- ↓3p, ↓9p, ↓p53, ↓FHIT, ↓p16, ↓p19
- ↑Cyclin D1, ↑EGFR, ↑COX-2
- ↓6p, ↓8p23, ↓4q26-q28

#### Esophagus
- ↑p16, ↑p53, ↑DNA Content
- ↑EGFR, ↑VEGFR, ↑Cyclin D1, ↑APC, ↑TGFα, ↑VEGF, ↑Cadherin

#### Liver
- HBV, HCV, Carcinogen/DNA Adducts
- ↑TGF, ↑IGF-2, ↑TNF-2, IL6, Genomic Instability
- Telomerase, c-MYC, ↓p53, ↓Rb, ↑IGF2-R, ↓PTEN, ↓DLC1, ↓p73, ↓E-Cadherin, Cyclin D, Cyclin E, p16, p21, p27, Aberrant Methylation
Genome Initiatives Contributing to Oncology Drug Development

The Cancer Genome Atlas (TCGA) — NCI, NHGRI

A comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. The pilot project is evaluating lung, brain, and ovarian cancers.

International HapMap Project—US, Canada, China, Japan, Nigeria, UK

The HapMap is a catalog of common genetic variants that occur in human beings. It describes what these variants are, where they occur in our DNA, and how they are distributed among people within populations and among populations in different parts of the world. The International HapMap Project is not using the information in the HapMap to establish connections between particular genetic variants and diseases. Rather, the Project is designed to provide information that other researchers can use to link genetic variants to the risk for specific illnesses, which will lead to new methods of preventing, diagnosing, and treating disease.
Complexity of Genomic/Proteomic Analysis

- Genes (23,000)
  - ↓ (3-5x)
- Allelic Variants
  - ↓ (3-5x)
- mRNA Splicing Variants
  - ↓ (3-5x)
- Protein Post-translational Modifications
  - ↓ (>10^6)
- Protein-Protein Interactions
“Field Cancerization”

Multiclonal Focal Expansions

Epithelial Sheet
**Beyond Detection:**
**Imaging as Cancer Biomarker Tissue vs Imaging Biomarkers**

<table>
<thead>
<tr>
<th>Tissue/Blood Biomarker</th>
<th>Imaging Biomarker</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Can probe many features</strong></td>
<td>Probes 1-2 features</td>
</tr>
<tr>
<td>Single location, limited sampling</td>
<td><strong>Tissue volume, full tumor burden sampling</strong></td>
</tr>
<tr>
<td><strong>Variable cost</strong></td>
<td>Often expensive</td>
</tr>
<tr>
<td>Invasive (tissue)</td>
<td><strong>Non-invasive</strong></td>
</tr>
<tr>
<td>Serial assay challenging</td>
<td><strong>Serial assay possible</strong></td>
</tr>
<tr>
<td><strong>Widely available — central assay</strong></td>
<td>Less widely available—local assay</td>
</tr>
</tbody>
</table>
Gene Expression Profile in Breast Cancer

ErbB Signaling Network

Ligands
(≥10)

EGF

NRG1

NRG2

Receptor
dimers
(≥10)

1 1 1 1

1 2 1 2

1 3 1 3

1 4 1 4

2 2 2 2

2 4 2 4

3 3 3 3

3 4 3 4

4 4 4 4

Effectors
(>50)

Cbl

PLC-γ

Shc

Src

Ras-GAP

PI3K

Proliferation
Survival
Migration
Angiogenesis

Promise of Imaging Science

Features of Imaging
• Non-invasive, optical biopsy
• Sequential/multiple sampling
• Quantitative localization
• Molecular target expression
  – Levels
  – Patterns

Applications
• Screening/early detection
• Early diagnosis
• Staging and therapy monitoring
• Drug development tool
  – Molecular target based drug screening
  – Imaging of drug biodistribution, in 3D and within tumor microenvironment
  – Target based validation in animal models
  – Imaging of drug –target interaction *in vivo*
  – Co-register drug distribution with drug target expression
  – Co-register drug distribution with drug effect
Why FDG-PET

- FDG-PET exploits the reliance of tumor cells on glucose and glycolytic metabolism to image cancers (Warburg Effect, strong mechanistic rationale)
- FDG-PET data can be assessed visually, or analyzed semiquantitatively or quantitatively
- FDG-PET is approved for use in the diagnosis, staging, and restaging of a variety of cancer types, and in these applications can significantly impact the clinical management of disease
- In a number of clinical settings (e.g., NSCLC, esophageal cancer, lymphoma), FDG-PET can provide an early measure of response to treatment with approved therapies
- With a few additional studies, FDG-PET could facilitate drug development and patient care by resulting in:
  - Shorter duration of Phase II studies to evaluate new drug/regimen
  - Accelerated approval in Phase III trials, with full approval contingent on evidence of clinical benefit (e.g., PFS, OS) after longer term follow-up
  - Better patient care by ceasing ineffective therapies earlier

## Centers for Medicare and Medicaid Services (CMS)
### Coverage for FDG-PET in Oncology

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>Coverage (Effective Date)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary Pulmonary Nodule</td>
<td>Characterization (January 1998)</td>
</tr>
<tr>
<td>Lung Cancer (non small cell)</td>
<td>Initial Staging (January 1998)</td>
</tr>
<tr>
<td></td>
<td>Diagnosis, staging and restaging (July 2001)</td>
</tr>
<tr>
<td>Esophageal Cancer</td>
<td>Diagnosis, staging and restaging (July 2001)</td>
</tr>
<tr>
<td>Colorectal Cancer</td>
<td>Tumor localization if CEA suggests recurrence (July 1999)</td>
</tr>
<tr>
<td></td>
<td>Diagnosis, staging and restaging (July 2001)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Evaluating recurrence, as an alternative to Gallium scan (July 1999)</td>
</tr>
<tr>
<td></td>
<td>Diagnosis, staging and restaging (July 2001)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>Staging and restaging, as an alternative to Gallium scan (July 1999)</td>
</tr>
<tr>
<td></td>
<td>Diagnosis, staging and restaging of Hodgkin and non-Hodgkin (July 2001)</td>
</tr>
<tr>
<td>Head and Neck Cancer (excluding CNS and Thyroid)</td>
<td>Diagnosis, staging and restaging (July 2001)</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>Adjunct for diagnosis, staging, restaging and monitoring response (October 2002);</td>
</tr>
<tr>
<td></td>
<td>particularly, as an adjunct for staging metastatic disease, restaging locoregional</td>
</tr>
<tr>
<td></td>
<td>recurrence or metastasis, and for monitoring response of locally advanced and</td>
</tr>
<tr>
<td></td>
<td>metastatic breast cancer when a change in therapy is anticipated</td>
</tr>
<tr>
<td>Thyroid Cancer (follicular cell)</td>
<td>Evaluating recurrent or residual follicular cell tumors (previously treated by thyroidectomy</td>
</tr>
<tr>
<td></td>
<td>and radiiodine ablation) when serum thyroglobulin &gt;10ng/ml and I-131 whole body scan</td>
</tr>
<tr>
<td></td>
<td>is negative (October 2003)</td>
</tr>
</tbody>
</table>
Why FDG-PET in Lung

- Relatively ineffective first line therapy in late stage disease
- Unmet medical need requiring new drugs/therapies
- Existing clinical FDG-PET data for diagnosis and staging
- Existing retrospective data on early response, suggesting criteria for ceasing ineffective therapy and allowing design of trials to evaluate new drugs
PET in NSCLC: Prediction of Response to Chemotherapy

Median TTP and overall survival longer for responders than non-responders (163 vs 54 days and 252 days vs 151 days, respectively)

FDG-PET as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in NSCLC

Patients with advanced NSCLC, who were scheduled to undergo palliative chemotherapy with an a two drug chemotherapy regimen (with or without Avastin)

Registration/Randomization
1:3 ratio

Group A:
- Two (2) PET scans prior to chemotherapy – at least 24 hours between the 2 pre-therapeutic scans
- One PET scan after the first chemotherapy cycle
- Follow-up CT scans per standard of care

Group B:
- One (1) PET at baseline (pre Cycle 1 of chemotherapy)
- One PET scan after the first chemotherapy cycle
- One PET scan after the second chemotherapy cycle
- Follow-up CT scans per standard of care.
Why FDG-PET in Lymphoma

- Successful clinical management
- Effective drugs
- Existing clinical FDG-PET data for diagnosis and staging
- Established treatment response criteria, that can be refined by FDG-PET
Lymphoma: Evaluation of Treatment Response
Access to FDG-PET/CT imaging is a requirement for institutions enrolling patients on the F18 FDG-PET validation CALGB 50303 study.
Initial Qualification of FDG-PET as a Surrogate Endpoint for Clinical Benefit

Baseline FDG-PET

→

Treat with Approved Chemotherapeutic Drug (Standard Therapy)

→

FDG-PET: Metabolic Response (Predetermined Response Level)

→

Continue Treatment to Clinical Endpoint(s)—e.g., OS, DFS, PFS, OR by Conventional Measurement
Further Qualification (e.g., 2 Different Drugs with Different Mechanisms in a Specific Target Organ) of FDG-PET as a Surrogate Endpoint for Clinical Benefit for Evaluation of New Therapies

- Baseline FDG-PET
- Treat with New Therapy
- FDG-PET: Metabolic Response (Predetermined Response Level)
  - If Response Is Met for Predetermined % of Patients, May Support Claim of Clinical Benefit and Accelerated Approval for New Therapy
- Continue Treatment to Clinical Endpoint(s) OR Carry Out Confirmatory Trial with Clinical Endpoint(s)
Validation of DCE-MRI Derived Biomarkers for Response to Therapy

- DCE MRI has been proposed as a means of predicting and monitoring response to cancer therapeutics.
- It measures tumor blood flow and so may be useful for prediction and monitoring of response to treatments that target the tumor vasculature including the VEGF pathway.
- Use of DCE-MRI has been limited by lack of standardization, and so this new project is aimed at establishing a rational, standardized approach to DCE MRI.
- The initial phase is development of an idealized, standardized DCE MRI data set using prostate cancer as a model to test various analytic approaches and trade-offs in the acquisition protocol that may be needed for broader application. The data will be made available to others interested in testing additional DCE-MRI analytic strategies.
Summary of I-SPY 2 Design

- Standard control (taxane-based)
- Balance randomization to new drugs initially
- Build predictive index for each therapy/biomarker combination
- Adaptively randomize
- Evaluate many drugs & combinations
  - Successes graduate to phase 3
  - Underperformers dropped for futility
Morphologic Patterns in Locally Advanced Neoadjuvant Breast Cancer Setting Detected by MR Volume

Nola M. Hylton, PhD
(I-SPY Project)
Molecular Targets of Cytotoxic and Cytostatic Drugs in the Pathways Controlling Glycolytic Metabolism

Kelloff et al., Clin Cancer Res 11:2785–808, 2005
Understanding the Warburg Effect: Metabolic Requirements of Cell Proliferation

Adapted from Vander Heiden et al., *Science* 324, 1029 -1033 (2009)

Published by AAAS
Value Proposition/Benefit for Partners in Public Private Partnership (PPP)

- **Patients:** Better Clinical Data, More Effective Treatment/Management
- **FDA:** Provides for Evidence-Based Regulatory Policy
- **Pharma:** More Efficient Drug Development and Approval Path, Better Early Response Criteria
- **Device Industry:** Larger Market for PET/CT and PET/MRI Scanners
- **CMS:** Helps Define Reasonableness and Need
- **Academia/NCI:** Better Clinical Data, More Effective Treatment/Management